Drug maker Adcock Ingram has reported a double-digit increase in full-year earnings and dividends even as the seller of brands such as Corenza C and Panado navigated a weak economy that saw consumers coming under increasing pressure.
It described its results as a"healthy financial and operational performance" amid a weak economy characterised by currency weakness and volatility. It also noted that SA's cash-strapped consumers had also been constrained during the period.